Anti-VEGFR2 monoclonal antibody(MSB0254) inhibits angiogenesis and tumor growth by blocking the signaling pathway mediated by VEGFR2 in glioblastoma
- 11 March 2022
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 604, 158-164
Abstract
No abstract availableKeywords
Funding Information
- Suzhou City Science and Technology Bureau (SYS2020123)
- Anhui Provincial Natural Science Foundation (1908085QH362)
This publication has 26 references indexed in Scilit:
- Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS TrialJournal of Clinical Oncology, 2016
- Ten years of anti-vascular endothelial growth factor therapyNature Reviews Drug Discovery, 2016
- Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive natureNeuro-Oncology, 2015
- Knockdown of the AKT3 (PKBγ), PI3KCA, and VEGFR2 genes by RNA interference suppresses glioblastoma multiforme T98G cells invasiveness in vitroTumor Biology, 2014
- A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2014
- An Open-Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX-6 as First-Line Therapy for Metastatic Colorectal CancerThe Oncologist, 2014
- A Randomized Trial of Bevacizumab for Newly Diagnosed GlioblastomaNew England Journal of Medicine, 2014
- A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular CancerClinical Cancer Research, 2013
- Molecular analysis of a recurrent glioblastoma treated with bevacizumabBrain Tumor Pathology, 2013
- Use of Gliadel (BCNU) Wafer in the Surgical Treatment of Malignant Glioma: A 10-Year Institutional ExperienceAnnals of Surgical Oncology, 2008